IDEAYA and Servier Launch Phase 3 Uveal Melanoma Trial
South San Francisco, California and Paris, France, September 9, 2026 IDEAYA Biosciences and Servier have announced that the first...
NMIBC
Advertisement
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
UroGen Submits NDA for UGN-103 Bladder Cancer Treatment
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
Ractigen Therapeutics Closes $31M Financing to Advance saRNA Pipeline
NANTONG, China, July 29, 2026 Ractigen Therapeutics has successfully closed a financing round exceeding $31 million (over RMB 200...
Advertisements
ImmunityBio Receives UAE Marketing Authorization for ANKTIVA
CULVER CITY, Calif., July 29, 2026 ImmunityBio announced that the Emirates Drug Establishment (EDE) has granted Marketing Authorization for...
CG Oncology Publishes Positive Phase 3 BOND-003 Results in The Lancet Oncology
DALLAS, July 27, 2026 CG Oncology, Inc. announced the publication of results from its pivotal Phase 3 BOND-003 Cohort...
UroGen Announces FDA Clearance of IND for UGN-501 in Bladder Cancer
PRINCETON, N.J., July 8, 2026 UroGen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared...
Hamlet BioPharma Advances Alpha1H into Phase 3 Trial
LUND, Sweden, June 17, 2026 Hamlet BioPharma AB has reached a major clinical development milestone with the successful completion...
Hamlet BioPharma Expands Alpha1H Trial for Bladder Cancer
LUND, Sweden, June 22, 2026 Hamlet BioPharma AB has announced a significant expansion of its U.S. clinical development program...
Advertisement
